Company intelligence / Profile preview

Borui Xinchuang Biomedical Technology

Wuxi, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

BGM0504, a synthetic peptide targeting both GIPR and GLP-1R, is being developed by Borui Xinchuang Biomedical Technology for the treatment of type 2 diabetes and obesity. The drug has reached Phase III clinical trials for weight management and Phase II trials for type 2 diabetes. No approved products yet; all programs are still under clinical investigation with no published efficacy results to date.

Therapeutic areas: Endocrinology
Modalities: Synthetic peptide
Industry: Biotech

Partnerships

BrightGene Bio-Medical Technology Co., Ltd.

Beyond the preview

Go deeper on Borui Xinchuang Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Borui Xinchuang Biomedical Technology.

Explore the full profile